Latest Insider Transactions at Bionano Genomics, Inc. (BNGO)
This section provides a real-time view of insider transactions for Bionano Genomics, Inc. (BNGO). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Bionano Genomics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Bionano Genomics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 11
2024
|
Mark Oldakowski Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,568
-5.5%
|
$0
$0.48 P/Share
|
|
Sep 11
2024
|
Alka Chaubey Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,075
-6.35%
|
$0
$0.48 P/Share
|
|
Jun 03
2024
|
Gulsen Kama Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
16,000
+50.0%
|
-
|
|
Jun 03
2024
|
Mark Oldakowski Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
16,000
+19.83%
|
-
|
|
Jun 03
2024
|
Alka Chaubey Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
16,000
+24.9%
|
-
|
|
Jun 03
2024
|
Jonathan V. Dixon GENERAL COUNSEL |
BUY
Grant, award, or other acquisition
|
Direct |
14,500
+44.58%
|
-
|
|
Jun 03
2024
|
R. Erik Holmlin PRESIDENT AND CEO |
BUY
Grant, award, or other acquisition
|
Direct |
44,000
+26.54%
|
-
|
|
Feb 15
2024
|
Jonathan V. Dixon GENERAL COUNSEL |
SELL
Payment of exercise price or tax liability
|
Direct |
402
-10.24%
|
$402
$1.27 P/Share
|
|
Feb 15
2024
|
R. Erik Holmlin PRESIDENT AND CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,073
-3.81%
|
$3,073
$1.27 P/Share
|
|
Feb 15
2024
|
Mark Oldakowski Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,229
-2.46%
|
$1,229
$1.27 P/Share
|
|
Feb 15
2024
|
Alka Chaubey Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,081
-3.32%
|
$1,081
$1.27 P/Share
|
|
Sep 18
2023
|
Mark Oldakowski Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
20,000
+5.92%
|
-
|
|
Sep 18
2023
|
Alka Chaubey Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
20,000
+12.14%
|
-
|
|
Jun 13
2023
|
Hannah Mamuszka Director |
BUY
Open market or private purchase
|
Direct |
65,789
+50.0%
|
$0
$0.76 P/Share
|
|
May 16
2023
|
R. Erik Holmlin PRESIDENT AND CEO |
BUY
Open market or private purchase
|
Direct |
15,000
+1.83%
|
$0
$0.64 P/Share
|
|
May 12
2023
|
Mark Oldakowski Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
41,496
-12.23%
|
$0
$0.66 P/Share
|
|
May 12
2023
|
Christopher P. Stewart Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
50,000
+15.09%
|
$0
$0.67 P/Share
|
|
May 12
2023
|
R. Erik Holmlin PRESIDENT AND CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
50,141
-5.96%
|
$0
$0.66 P/Share
|
|
Feb 15
2023
|
Christopher P. Stewart Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
105,000
+31.22%
|
-
|
|
Feb 15
2023
|
Alka Chaubey Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
120,000
+49.02%
|
-
|
|
Feb 15
2023
|
Mark Oldakowski Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
120,000
+26.12%
|
-
|
|
Feb 15
2023
|
R. Erik Holmlin PRESIDENT AND CEO |
BUY
Grant, award, or other acquisition
|
Direct |
300,000
+26.28%
|
-
|
|
Aug 15
2022
|
Yvonne Linney Director |
SELL
Open market or private sale
|
Direct |
20,000
-100.0%
|
$60,000
$3.62 P/Share
|
|
Aug 15
2022
|
Yvonne Linney Director |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+50.0%
|
$0
$0.38 P/Share
|
|
Jul 07
2022
|
David L Barker Director |
BUY
Exercise of conversion of derivative security
|
Direct |
44,470
+43.24%
|
$0
$0.51 P/Share
|
|
May 16
2022
|
David L Barker Director |
BUY
Open market or private purchase
|
Direct |
10,000
+41.85%
|
$10,000
$1.6 P/Share
|
|
May 13
2022
|
Christopher P. Stewart Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
60,000
+33.04%
|
$0
$0.56 P/Share
|
|
May 12
2022
|
R. Erik Holmlin PRESIDENT AND CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
50,141
-8.52%
|
$50,141
$1.41 P/Share
|
|
May 12
2022
|
Mark Oldakowski Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
41,496
-16.07%
|
$41,496
$1.41 P/Share
|
|
Nov 29
2021
|
R. Erik Holmlin PRESIDENT AND CEO |
BUY
Open market or private purchase
|
Indirect |
5,025
+29.44%
|
$15,075
$3.98 P/Share
|
|
Nov 19
2021
|
Christopher P. Stewart Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
22,500
+28.85%
|
$0
$0.56 P/Share
|
|
Oct 18
2021
|
Soheil Shams Chief Informatics Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,325,378
+50.0%
|
-
|
|
May 26
2021
|
Christopher P. Stewart Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+43.1%
|
$0
$0.56 P/Share
|
|
May 12
2021
|
Mark Oldakowski Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
240,000
+48.77%
|
-
|
|
May 12
2021
|
R. Erik Holmlin PRESIDENT AND CEO |
BUY
Grant, award, or other acquisition
|
Direct |
580,000
+41.35%
|
-
|
|
Jan 22
2021
|
Christopher P. Stewart Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
8,000
+50.0%
|
$48,000
$6.0 P/Share
|